Medical Advocates

Efavirenz
(Sustiva/Strocrin)
 
Journal Citations:
Treatment Strategies

Dosage Adjustment
Simplification Therapy
Intensification Therapy
Treatment Interruption
Hepatic Disease
Renal Disease
Metabolic Disorders
HIV/HCV Coinfection
HIV/TB Coinfection

 

Efavirenz Adult Treatment Main New/Newsworthy Home Page      

Last Update:  December 11, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

Dosage Adjustment
 

 
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome
P450 2B6 *6 and *26.
Gatanaga H, Hayashida T, Tsuchiya K, et al  
Clin Infect Dis. 2007 Nov 1;45(9):1230-7.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Outcomes of dosage adjustments used to manage antiretroviral drug interactions.
Park-Wyllie LY, Levine MA, Holbrook A, et al
Clin Infect Dis.
2007 Oct 1;45(7):933-

Abstract  


Simplification Therapy
 

  Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with
nevirapine, efavirenz or abacavir.
de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS.
2005 Sep 2;19(13):1385-139
1.
Abstract

Intensification Therapy
 

  A WEEK-IN-REVIEW FEATURED REPORT
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected
patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, et al
AIDS. 2007 Apr 23;21(7):813-823.
Abstract

Treatment Interruption
 

 
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic
resistance after treatment interruption.
Darwich L, Esteve A, Ruiz L, et al
Antivir Ther
. 2008;13(7):945-51.

Abstract

Hepatic Disease
 

  Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM
of EFV.

Katsounas A, Frank A, Klinker H, Langmann P.
Eur J Med Res. 2007 Aug 16;12(8):331-6
Abstract

Renal Disease
 

  Experience with efavirenz in end-stage renal disease.
Prime KP, Woolfson RG, Pakianathan MR
Int J STD AIDS. 2003 Jul;14(7):497-8.
Abstract

Metabolic Disorders
 

 
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active
antiretroviral therapy.

Pérez-Molina JA, Domingo P, Martínez E, Moreno S.
J Antimicrob Chemother.
2008 May 14
Abstract

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in
HIV-infected patients.
Pereira SA, Branco T, Corte-Real RM,
Br J Clin Pharmacol. 2006 May;61(5):601-4

Abstract

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the
management of dyslipidaemia.
Calza L, Manfredi R, Colangeli V, et al 
AIDS. 2005 Jul 1;19(10):1051-8. R

Abstract

HIV/HCV Coinfection
 

 
Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-
Coinfected Patients.
Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
J Acquir Immune Defic Syndr
. 2008 Jul 23.
Abstract

HIV/Tuberculosis Coinfection
 

 
Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients:
Pharmacogenetic Effect of CYP2B6 Variation.

Kwara A, Lartey M, Sagoe KW, et al  
J Clin Pharmacol.
2008 Sep;48(9):1032-40.
Abstract
 
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels
but excellent clinical outcomes in patients treated for tuberculosis and HIV.

Friedland G, Khoo S, Jack C, Lalloo U.  
J Antimicrob Chemother
. 2006 Oct 10;
Abstract

Efavirenz trough levels are not associated with virological failure throughout therapy
with 800 mg daily and a rifampicin-containing antituberculosis regimen
.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al

J Antimicrob Chemother. 2006 Sep 6;
Abstract
 


Efavirenz Adult Treatment Main New/Newsworthy Home Page      

Efavirenz Journal Citations: Adult/Adolescent Treatment